The FDA has granted emergency use authorization for Novavax's updated COVID-19 vaccine, which targets the JN.1 strain and is approved for individuals aged 12 and older. This comes shortly after similar approvals for updated vaccines from Pfizer and Moderna, which target the KP.2 variant, a descendant of JN.1. Novavax's protein-based vaccine offers an alternative for those who are hesitant about mRNA vaccines. The vaccine is expected to be available in thousands of locations, including pharmacies, making it easier to administer. Despite waning demand for vaccines, Novavax aims to meet steady interest as health officials encourage vaccination ahead of potential winter surges of COVID-19. The FDA emphasized the importance of having multiple vaccine options to ensure public health safety.